Literature DB >> 15036119

GSTM1 null genotype as a risk factor for anti-BPDE-DNA adduct formation in mononuclear white blood cells of coke-oven workers.

Sofia Pavanello1, Ewa Siwinska, Danuta Mielzynska, Erminio Clonfero.   

Abstract

The influence of the genetic deletion polymorphism of glutathione S-transferase micro 1 (GSTM1 *0/*0) on levels of anti (+/-)-r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene (anti-BPDE-DNA) adduct in the peripheral blood lymphocyte plus monocyte fraction (LMF) of coke-oven workers was investigated. A total of 95 male Polish coke-oven workers (60% current smokers) from two different plants comprised the sample population. Polycyclic aromatic hydrocarbons (PAH) exposure was assessed by means of the individual post-shift urinary excretion of 1-pyrenol (mean +/- S.D.: 6.93 +/- 7.20 micromol/mol creatinine; 70% of the subjects exceeded the proposed biological exposure index (BEI) 2.28 micromol/mol creatinine). Anti-BPDE-DNA adduct levels were detected by high performance liquid chromatography (HPLC)/fluorescence analysis of the anti-BPDE tetrol I-1 released after acid hydrolysis of DNA samples. Genotypes were determined by polymerase chain reaction (PCR) on the genomic DNA of each subject. Coke-oven workers without active GSTM1 (GSTM1 *0/*0, 33%) had significantly higher adduct levels than those with active GSTM1 (GSTM1*1/*1 and *1/*0) (5.90 +/- 5.59 versus 3.25 +/- 2.01 adducts/10(8) bases, Mann-Whitney U-test, z = 2.53, P = 0.011), PAH exposure in the two subgroups being similar (7.06 +/- 6.83 versus 6.67 +/- 8.00 1-pyrenol micromol/mol creatinine). The highest number of GSTM1 null subjects (12/23, 39%) belonged to the quartile with the highest adduct levels (i.e., >4.67 adducts/10(8) nucleotides). That is, coke-oven workers with GSTM1 *0/*0 genotype had a significantly higher risk of having high adduct levels than individuals with active GSTM1 genotype (Fisher exact test P = 0.0355; odds ratio (OR) = 4.145, 95% CI 1.0-18.8). Multiple linear regression analysis showed that the increase in anti-BPDE-DNA adduct levels in LMF was significantly related to the high occupational exposure to PAHs (benzo[a]pyrene (BaP)) of coke-oven workers (t = 3.087, P < 0.01) and to the lack of GSTM1 activity (t = 3.512, P < 0.001), rather than to the two other confounding factors of PAH intake, i.e. charcoal-broiled meat consumption and smoking habits. In conclusion, our results indicate the clear influence of the GSTM1 detoxifying genotype on anti-BPDE-DNA adduct formation in the LMF of coke-oven workers. This is invaluable for future environmental-occupational studies using this biomarker of PAH exposure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036119     DOI: 10.1016/j.mrgentox.2003.10.019

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  4 in total

Review 1.  Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis.

Authors:  Benjamin A Rybicki; Nora L Nock; Adnan T Savera; Deliang Tang; Andrew Rundle
Journal:  Cancer Lett       Date:  2005-09-09       Impact factor: 8.679

2.  Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing.

Authors:  Erin Madeen; Lisbeth K Siddens; Sandra Uesugi; Tammie McQuistan; Richard A Corley; Jordan Smith; Katrina M Waters; Susan C Tilton; Kim A Anderson; Ted Ognibene; Kenneth Turteltaub; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2018-12-21       Impact factor: 4.219

3.  Association between a urinary biomarker for exposure to PAH and blood level of the acute phase protein serum amyloid A in coke oven workers.

Authors:  Niels Hadrup; Danuta Mielżyńska-Švach; Agnieszka Kozłowska; Manuela Campisi; Sofia Pavanello; Ulla Vogel
Journal:  Environ Health       Date:  2019-09-02       Impact factor: 5.984

Review 4.  Polycyclic aromatic hydrocarbons and PAH-related DNA adducts.

Authors:  Błaszczyk Ewa; Mielżyńska-Švach Danuta
Journal:  J Appl Genet       Date:  2016-12-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.